Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 3 5 M IN PLASTIC CONTAINER versus TRAVASOL 8 5 W ELECTROLYTES.
AMINOSYN II 3.5% M IN PLASTIC CONTAINER vs TRAVASOL 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 3.5% M is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral/enteral nutrition. The 'M' formulation includes electrolytes and trace elements. Amino acids are incorporated into endogenous proteins, serving as substrates for gluconeogenesis, oxidative metabolism, and neurotransmitter synthesis.
Travasol 8.5% with Electrolytes is a parenteral nutrition solution providing amino acids for protein synthesis, electrolytes for maintenance of acid-base balance and osmotic pressure, and calories to prevent protein catabolism and promote anabolism.
Intravenous administration; typical adult dose is 1 to 2 g amino acids/kg/day, corresponding to 30 to 60 mL/kg/day of 3.5% solution; infusion rate not to exceed 0.1 g amino acids/kg/hour.
Intravenous infusion via central vein: 500 mL to 2000 mL per day, infused at a rate not exceeding 0.2 g/kg/hour of amino acids. Dosing individualized based on caloric and protein requirements.
None Documented
None Documented
Variable; amino acids have short plasma half-lives (minutes to hours) due to rapid cellular uptake and metabolism; no meaningful terminal half-life for the mixture.
Variable; amino acids have rapid distribution (minutes) and metabolic elimination (half-life ~1-2 hours for most). Clinical context: continuous infusion maintains steady state; half-life not typically used for dosing but reflects rapid clearance.
100% renal; amino acids are deaminated and metabolized to urea, which is excreted renally; minimal (<1%) biliary/fecal excretion.
Components are eliminated via metabolic pathways (e.g., amino acids undergo deamination, protein synthesis) and renal excretion of waste products (urea, creatinine). 100% of nitrogenous waste is renally excreted; electrolytes are excreted renally proportional to intake and renal function.
Category C
Category C
Amino Acid Solution
Amino Acid Solution